Literature DB >> 14963124

Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells.

Lokesh Agrawal1, Xihua Lu, Jin Qingwen, Zainab VanHorn-Ali, Ioan Vlad Nicolescu, David H McDermott, Philip M Murphy, Ghalib Alkhatib.   

Abstract

CCR5Delta32 is a loss-of-function mutation that abolishes cell surface expression of the human immunodeficiency virus (HIV) coreceptor CCR5 and provides genetic resistance to HIV infection and disease progression. Since CXCR4 and other HIV coreceptors also exist, we hypothesized that CCR5Delta32-mediated resistance may be due not only to the loss of CCR5 function but also to a gain-of-function mechanism, specifically the active inhibition of alternative coreceptors by the mutant CCR5Delta32 protein. Here we demonstrate that efficient expression of the CCR5Delta32 protein in primary CD4(+) cells by use of a recombinant adenovirus (Ad5/Delta32) was able to down-regulate surface expression of both wild-type CCR5 and CXCR4 and to confer broad resistance to R5, R5X4, and X4 HIV type 1 (HIV-1). This may be important clinically, since we found that CD4(+) cells purified from peripheral blood mononuclear cells of individuals who were homozygous for CCR5Delta32, which expressed the mutant protein endogenously, consistently expressed lower levels of CXCR4 and showed less susceptibility to X4 HIV-1 isolates than cells from individuals lacking the mutation. Moreover, CD4(+) cells from individuals who were homozygous for CCR5Delta32 expressed the mutant protein in five of five HIV-exposed, uninfected donors tested but not in either of two HIV-infected donors tested. The mechanism of inhibition may involve direct scavenging, since we were able to observe a direct interaction of CCR5 and CXCR4 with CCR5Delta32, both by genetic criteria using the yeast two-hybrid system and by biochemical criteria using the coimmunoprecipitation of heterodimers. Thus, these results suggest that at least two distinct mechanisms may account for genetic resistance to HIV conferred by CCR5Delta32: the loss of wild-type CCR5 surface expression and the generation of CCR5Delta32 protein, which functions as a scavenger of both CCR5 and CXCR4.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14963124      PMCID: PMC369216          DOI: 10.1128/jvi.78.5.2277-2287.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Recombinant vaccinia viruses. Design, generation, and isolation.

Authors:  C C Broder; P L Earl
Journal:  Mol Biotechnol       Date:  1999-12-15       Impact factor: 2.695

2.  A human immunodeficiency virus type 1 isolate from an infected person homozygous for CCR5Delta32 exhibits dual tropism by infecting macrophages and MT2 cells via CXCR4.

Authors:  Hassan M Naif; Anthony L Cunningham; Mohammed Alali; Shan Li; Najla Nasr; Marc M Buhler; Dominique Schols; Erik de Clercq; Graeme Stewart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

4.  Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1.

Authors:  R I Connor; W A Paxton; K E Sheridan; R A Koup
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

5.  Determinants of the trans-dominant negative effect of truncated forms of the CCR5 chemokine receptor.

Authors:  M Chelli; M Alizon
Journal:  J Biol Chem       Date:  2001-10-12       Impact factor: 5.157

6.  Influence of the CCR2-V64I polymorphism on human immunodeficiency virus type 1 coreceptor activity and on chemokine receptor function of CCR2b, CCR3, CCR5, and CXCR4.

Authors:  B Lee; B J Doranz; S Rana; Y Yi; M Mellado; J M Frade; C Martinez-A; S J O'Brien; M Dean; R G Collman; R W Doms
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  Chemokine receptors: emerging opportunities for new anti-HIV therapies.

Authors:  Lokesh Agrawal; Ghalib Alkhatib; Lokesh Agrawal
Journal:  Expert Opin Ther Targets       Date:  2001-06       Impact factor: 6.902

8.  Evidence of paired M2 muscarinic receptors.

Authors:  L T Potter; L A Ballesteros; L H Bichajian; C A Ferrendelli; A Fisher; H E Hanchett; R Zhang
Journal:  Mol Pharmacol       Date:  1991-02       Impact factor: 4.436

9.  Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.

Authors:  M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien
Journal:  Science       Date:  1996-09-27       Impact factor: 47.728

10.  Cooperativity manifest in the binding properties of purified cardiac muscarinic receptors.

Authors:  K A Wreggett; J W Wells
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

View more
  49 in total

Review 1.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

2.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 3.  Modulation of chemokine receptor activity through dimerization and crosstalk.

Authors:  C L Salanga; M O'Hayre; T Handel
Journal:  Cell Mol Life Sci       Date:  2009-04       Impact factor: 9.261

4.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

Review 5.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

6.  Resistance to human immunodeficiency virus type 1 (HIV-1) generated by lentivirus vector-mediated delivery of the CCR5{Delta}32 gene despite detectable expression of the HIV-1 co-receptors.

Authors:  Qingwen Jin; Jon Marsh; Kenneth Cornetta; Ghalib Alkhatib
Journal:  J Gen Virol       Date:  2008-10       Impact factor: 3.891

7.  Targeted chromosomal deletions in human cells using zinc finger nucleases.

Authors:  Hyung Joo Lee; Eunji Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2009-12-01       Impact factor: 9.043

8.  Direct observation of chemokine receptors 5 on T-lymphocyte cell surfaces using fluorescent metal nanoprobes 2: Approximation of CCR5 populations.

Authors:  Jian Zhang; Yi Fu; Ge Li; Richard Y Zhao; Joseph R Lakowicz
Journal:  Biochem Biophys Res Commun       Date:  2011-02-26       Impact factor: 3.575

Review 9.  Unveiling Human Non-Random Genome Editing Mechanisms Activated in Response to Chronic Environmental Changes: I. Where Might These Mechanisms Come from and What Might They Have Led To?

Authors:  Loris Zamai
Journal:  Cells       Date:  2020-10-27       Impact factor: 6.600

10.  The potent anti-HIV activity of CXCL12gamma correlates with efficient CXCR4 binding and internalization.

Authors:  Jeffrey D Altenburg; Qingwen Jin; Bashar Alkhatib; Ghalib Alkhatib
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.